Experienced investment executive focused on growth equity and operational improvement across technology and healthcare sectors. Carol Smith brings senior experience in portfolio management, deal sourcing, and strategic finance, having led cross-functional teams and executed bolt-on acquisitions. Known for structuring value-oriented investments, driving EBITDA expansion and supporting board-level governance; frequently engages with LPs, CFOs and founders on capital strategies and exit planning.
Experienced investment executive focused on growth equity and operational improvement across technology and healthcare sectors. Carol Smith brings senior experience in portfolio management, deal sourcing, and strategic finance, having led cross-functional teams and executed bolt-on acquisitions. Known for structuring value-oriented investments, driving EBITDA expansion and supporting board-level governance; frequently engages with LPs, CFOs and founders on capital strategies and exit planning.
Prefers growth-equity investments in technology and healthcare where active operational stewardship can accelerate revenue and EBITDA expansion. Emphasizes structured, value-oriented deals with clear governance and board engagement, often deploying bolt‑on M&A to deepen product or market positions. Focuses on cross‑functional diligence, aligning management incentives and capital structures to optimize exit timing and LP outcomes. Time horizon is medium-to-long term, balancing growth upside with disciplined downside protection through covenants, staged financings and conservative leverage. Competitive edge derives from hands-on portfolio operations, strategic finance expertise and strong founder/CFO relations to execute scaling plans.
Prefers growth-equity investments in technology and healthcare where active operational stewardship can accelerate revenue and EBITDA expansion. Emphasizes structured, value-oriented deals with clear governance and board engagement, often deploying bolt‑on M&A to deepen product or market positions. Focuses on cross‑functional diligence, aligning management incentives and capital structures to optimize exit timing and LP outcomes. Time horizon is medium-to-long term, balancing growth upside with disciplined downside protection through covenants, staged financings and conservative leverage. Competitive edge derives from hands-on portfolio operations, strategic finance expertise and strong founder/CFO relations to execute scaling plans.
| Trades 650 | Longs Won 385/650 59% | Profit Factor 3.44 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $1.33M |
| Average Win $410,285.35 | Best Trade (Jul 10) $23.89M | Sharpe Ratio -10.59 |
| Average Loss -$173,306.93 | Worst Trade (Mar 31) -$4.38M | Z-Score 6.87 (100%) |
| Commissions $0 | Avg. Trade Length 1y 2m 3w 5d | Expectancy $172,359.27 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.01% |
| Consecutive Losing Trades | 2,513 | 2,261 | 2,010 | 1,759 | 1,508 | 1,256 | 1,005 | 754 | 503 | 251 |